Dow futures pick up steam early Wednesday as Pfizer/BioNTech release preliminary lab study on omicron variant


U.S. stock-index futures gained some altitude higher Wednesday morning after a preliminary lab study from Pfizer

and BioNTech SE

suggested that 3 shots of their COVID vaccines, including a booster, provides the same level of neutralizing protection against the new omicron variant as two doses against the original strain of the coronvirus that causes COVID-19. Futures for the Dow Jones Industrial Average


were trading 177 points, or 0.5%, higher at 35,885, those for the S&P 500


were up 0.5% at 4,705, while the Nasdaq-100 futures were trading 0.4% higher at 16,375. “Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection,” the Pfizer/BioNTech report said. That report comes after South Africa reported findings from early lab tests indicating the Pfizer-BioNTech vaccine generated one-fortieth of the infection-fighting antibodies against omicron than against the original version of the virus.